Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
3
×
Tags
life sciences
national blog main
national top stories
san francisco blog main
3
×
san francisco top stories
biotech
boston blog main
boston top stories
clinical trials
data
new york blog main
new york top stories
amgen
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
cancer
cancer immunotherapy
cancer vaccine
cholesterol
chronic kidney disease
clinical study
detroit blog main
detroit top stories
disease
enzyme
fda
food and drug administration
forty seven
gag
gene editing
genome editing
hunter syndrome
ids
inclisiran
indiana blog main
indiana top stories
investing
ipo
ldl
What
nasdaq
3
×
medicine
therapeutics
week
aces
announced
benefit
big
biotechs
ceo
cholesterol
club
companies
continued
crop
drug
editing
exceeded
firms
flexible
gene
going
group
haul
humans
inclisiran
ipo
isn't
joined
key
landmark
latest
life
little
lowering
meant
medco
medicines
met
million
Language
unset
Current search:
nasdaq
×
photo
×
" san francisco blog main "
×
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M